Introduction
Since their introduction in the early 1960s, human menopausal 1 Department of Obstetrics and Gynecology, Rambam Medical gonadotrophins (HMG) have been used in ovulation induction Center, 2 Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel and 3 NV Organon, Oss, The Netherlands cycles, particularly during the last 2 decades in IVF programmes. Typically, human chorionic gonadotrophin (HCG) 4 To whom correspondence should be addressed at: Department of is used as a surrogate to luteinizing hormone (LH) for oocyte Obstetrics and Gynecology, Rambam Medical Center, POB 9602, Haifa, Israel 31096. E mail: Itskovitz@rambam.health.gov.il maturation and induction of ovulation. Given its significantly longer half-life [Ͼ24 h versus 60 min for LH (Yen et al., 
A new treatment option for patients undergoing ovarian
1968; Damewood et al., 1989) ], HCG administration results stimulation is the gonadotrophin-releasing hormone in a prolonged luteotrophic effect, characterized by the develop-(GnRH) antagonist protocol, with the possibility to trigger ment of multiple corpora lutea and supraphysiological levels a mid-cycle LH surge using a single bolus of GnRH agonist, of oestradiol and progesterone. This sustained luteotrophic reducing the risk of developing ovarian hyperstimulation effect may result in the development of ovarian hyperstimulasyndrome (OHSS) in high responders and the chance of tion syndrome (OHSS), the most frequent and severe complicacycle cancellation. This report describes the use of 0.2 mg tion of HMG treatment (Golan et al., 1989) . The threat of triptorelin (Decapeptyl ® ) to trigger ovulation in eight OHSS often leads to cycle cancellation. patients who underwent controlled ovarian hyperstimulaAn alternative to HCG-induced ovulation triggering, is the tion with recombinant FSH (rFSH, Puregon ® ) and concomuse of gonadotrophin releasing hormone (GnRH) agonists. itant treatment with the GnRH antagonist ganirelix These compounds induce a sustained (Ͼ24 h) release of LH (Orgalutran ® ) for the prevention of premature LH surges.
(and FSH) from the pituitary, that effectively induces oocyte All patients were considered to have an increased risk for maturation and ovulation. Importantly, they also provide a developing OHSS (at least 20 follicles ≥11 mm and/or means by which OHSS is effectively prevented (Itskovitz serum oestradiol at least 3000 pg/ml). On the day of et al., 1988 Gonen et al., 1990; Emperaire et al., 1991 ; triggering the LH surge, the mean number of follicles Imoedemhe et al., 1991; Segal et al., 1992; Lanzone et al. , ≥11 mm was 25.1 ⍨ 4.5 and the median serum oestradiol 1994; Lewit et al., 1995 Lewit et al., , 1996 . concentration was 3675 (range 2980-7670) pg/ml. After
The major limitation of the use of GnRH agonist to trigger GnRH agonist injection, endogenous serum LH and FSH ovulation is that GnRH agonists are ineffective in women with surges were observed with median peak values of 219 and a low gonadotrophin reserve or after pituitary down-regulation 19 IU/l respectively, measured 4 h after injection. The with a GnRH agonist. In these situations, the pituitary is mean number of oocytes obtained was 23.4 ⍨ 15.4, of unresponsive for inducing an endogenous LH surge. Since which 83% were mature (metaphase II). None of the GnRH agonist-based protocols are routinely used in most IVF patients developed any signs or symptoms of OHSS. So programmes, the application of GnRH agonist for induction far, four clinical pregnancies have been achieved from the of ovulation has been limited. embryos obtained during these cycles, including the first
The recent introduction of GnRH antagonist protocols birth following this approach. It is concluded that GnRH (Albano et al., 1997; Ganirelix Dose Finding Group, 1998 ; agonist effectively triggers an endogenous LH surge for final has offered new opportunities of oocyte maturation after ganirelix treatment in stimulated using GnRH agonist to trigger ovulation and preventing OHSS cycles. Our preliminary results suggest that this regimen due to the mechanism of action of GnRH antagonists, i.e. may prove effective in triggering ovulation and could be competitive inhibition and relatively short duration of action. said to prevent OHSS in high responders. The efficacy Studies in monkeys (Chillik et al., 1987) have clearly demonand safety of such new treatment regimen needs to be strated that although tonic gonadotrophins remain suppressed established in comparative randomized studies.
under GnRH antagonist treatment, acute LH release can be Key words: GnRH agonist/GnRH antagonist/ovarian hyperelicited in a GnRH challenge test. In small scale studies in stimulation syndrome/recombinant FSH/triggering ovulation humans, it was demonstrated (Felberbaum et al., 1995) that under GnRH antagonist treatment the pituitary retains its responsiveness to GnRH, while others (Olivennes et al., 1996) Materials and methods showed in stimulation cycles for intrauterine insemination that reported minimal effective dose of GnRH antagonists (0.25 was added, until at least three follicles with a diameter of ജ17 mm mg, daily; Ganirelix Dose Finding Group, 1998), it is most were observed by ultrasound. Ovulation was routinely triggered with probable that ovulation can be safely and effectively triggered 10 000 IU HCG.
with a GnRH agonist. single GnRH agonist injection was given to induce final oocyte maturation prior to retrieval. An adequate pituitary response to GnRH agonist given 30 h after the last injection of ganirelix Results was documented by the occurrence of endogenous LH and The mean age and weight of the eight women were 26 years FSH surges, which were comparable to those described nearly (range 22-36 years) and 62 kg (range 50-83 kg) respectively. a decade ago in patients undergoing ovulation induction without All patients were scheduled for ICSI. The main causes of pituitary suppression (Itskovitz et al., 1991) . Our findings are infertility were male factor in five couples, oligomenorrhoea in line with previous studies (Chillik et al., 1987; Felberbaum in one patient, amenorrhoea with polycystic ovary syndrome et al., 1995; Olivennes et al., 1996) , which demonstrated that in one patient, and unknown in one couple.
an effective LH surge can be elicited with a GnRH agonist Table I presents the stimulation characteristics of each when pituitary suppression is established by GnRH antagonistpatient including the total amount of rFSH administered, the induced competitive inhibition of native GnRH. number of follicles, serum oestradiol levels and the number
The fact that 83% of the oocytes retrieved were mature and maturity of recovered oocytes. On the day of triggering clearly documents the adequacy of the gonadotrophin surges ovulation the mean number of follicles ജ11 mm was 25.1 Ϯ in initiating the final oocyte maturation process. 4.5 and the median serum oestradiol concentration was 3675
The limited clinical experience presented here supports a (range 2980-7670) pg/ml. The mean (ϮSD) number of oocyte major advantage of GnRH antagonist protocols in allowing retrieved was 23.4 (Ϯ15.4), of which 83% were metaphase II the use of GnRH agonist to trigger and prevent OHSS (Itskovitz oocytes. In one patient (108, see Table I ) one oocyte was et al., 1988 Lewit et al., 1995 Lewit et al., , 1996 . The rapid fall of oestrogen concentrations after embryo transfer, the lack of recovered, whereas 22 follicles ജ11 mm were observed by mid-luteal oestradiol peak, as well as the absence of free pelvic ultrasound. This patient had repeated unsuccessful treatment fluid suggest that triggering of final oocyte maturation with with a long protocol of GnRH agonist and HCG for triggering GnRH agonist may lead to a more physiological luteal phase ovulation and was diagnosed as suffering from an empty oestradiol and progesterone concentrations. This moderate follicle syndrome. In the other seven patients the total mean response is in sharp contrast with the exaggerated luteotrophic (ϮSD) number of embryos obtained was 15.4 Ϯ 6.6 per effect often seen after ovulation triggering with HCG (Itskovitzpatient. There were 88 good quality embryos and seven fresh Eldor et al., 1993) . The introduction of the GnRH agonist embryo transfers and for six patients, surplus embryos were induced triggering of ovulation in GnRH antagonist protocols frozen (in total 83).
would offer additional benefits to all patients, i.e. both high Table II depicts median serum LH, FSH, progesterone and and normal responders, though the efficacy and safety of such oestradiol concentrations after the bolus injection of 0.2 mg new treatment regimen needs to be established in comparative, triptorelin. Serum LH concentrations rose rapidly from 2.4 IU/l randomized studies. The relatively low pregnancy rate in our just prior to triptorelin administration to peak values of 219 limited series should be assessed in larger scale clinical studies. IU/l at 4 h after injection. Median LH concentrations were 71
In summary, we have demonstrated the ability of a single and 7.9 IU/l at 10-12 h and 34-36 h (at oocyte retrieval) bolus of 0.2 mg triptorelin to trigger an adequate LH surge in respectively. Serum FSH started to increase only at 2 h after stimulation cycles using a GnRH antagonist protocol. Our triptorelin injection and a median peak value of 18.6 IU/l was results suggest that this regimen may prove highly effective measured at 4 h. By the day of oocyte retrieval, serum FSH in terms of OHSS prevention, though further studies are needed had returned to its pre-dose value (5.4 IU/l).
to establish this potential advantage. Median serum oestradiol concentrations remained high during the first 12 h after triptorelin injection (4775-6000 pg/ml), but rapidly decreased thereafter to 2375, 963 and 69 pg/ml at References the day of oocyte retrieval, day of embryo transfer, and the Albano, C., Smitz, J., Camus, M. et al. (1997) Comparison of different doses end of the luteal phase respectively. A mid-luteal oestradiol of gonadotropin-releasing hormone antagonist Cetrorelix during controlled peak was not observed. None of the patients developed signs ovarian hyperstimulation. Fertil. Steril., 67, [917] [918] [919] [920] [921] [922] or symptoms of OHSS. Importantly, none of the patients had Chillik, C.F., Itskovitz, J., Hahn, D.W. et al. (1987) Characterizing pituitary free pelvic fluid when assessed by vaginal ultrasound during response to a gonadotropin-releasing hormone (GnRH) antagonist in monkeys: tonic follicle-stimulating hormone/luteinizing hormone secretion the luteal phase.
versus acute GnRH challenge tests before, during, and after treatment.
Fresh transfers resulted in one positive HCG test. Seventeen Fertil. Steril., 48, [480] [481] [482] [483] [484] [485] frozen-thawed cycles with embryos obtained during these Damewood, M.D., Shen, W., Zacur, H.A. et al. (1989) delivery of a healthy newborn.
